IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2979
-0.0082 (-2.68%)
At close: Dec 5, 2025, 4:00 PM EST
0.3000
+0.0021 (0.70%)
After-hours: Dec 5, 2025, 8:00 PM EST
Company Description
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.
The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.
Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Ram Mukunda |
Contact Details
Address: 10224 Falls Road Potomac, Maryland 20854 United States | |
| Phone | 301 983 0998 |
| Website | igcpharma.com |
Stock Details
| Ticker Symbol | IGC |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001326205 |
| CUSIP Number | 45408X308 |
| ISIN Number | US45408X3089 |
| Employer ID | 20-2760393 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Mukunda | Founder, President, Chief Executive Officer and Director |
| Claudia Grimaldi | Vice President, Principal Financial Officer, Chief Compliance Officer and Non-Independent Director |
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Rohit Goel CPA, M.B.A. | Director of Accounting and Senior Director |
| Susana Salgar | Sales Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 17, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 14, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | 8-K | Current Report |
| Oct 14, 2025 | 8-K | Current Report |
| Oct 1, 2025 | 8-K | Current Report |
| Sep 19, 2025 | 424B5 | Filing |
| Aug 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 18, 2025 | DEF 14A | Other definitive proxy statements |